Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 111

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 111
---
 successful registrational programs for
Radicava® (edaravone) for the treatment of Amyotrophic Lateral Sclerosis. From April 2003 to March 2012, Dr. Palumbo was Global
Head and Franchise Medical Leader for Psychiatry, and the Interim Head of Global Neuroscience at Johnson & Johnson, where he led
the medical teams who achieved successful global registrations for Risperdal® (risperidone); Concerta® (methylphenidate HCL);
and Invega® (paliperidone). He was Head of Psychiatry and Neurology at Pharmanet for from April 2002 to April 2003. Dr Palumbo previously
held industry positions in European Pharma with Sanofi-Synthelabo from April 1999 to April 2002, Biotech at Cephalon, from April 1997
to April 1998, and from July 1989 to April 2002, he held senior leadership and hospital administration roles at prestigious academic
research institutions including Yale, Cornell, and the University of Pennsylvania. He holds a Bachelor of Arts at the University of Pennsylvania
and received his Doctor of Medicine at the George Washington University School of Medicine. He was a Biological Sciences Training Program
Fellow of the National Institutes of Health and Chief Resident for the Abraham Ribicoff Clinical Neuroscience Research Unit at Yale University.
Dr Palumbo has received Board Certification in Psychiatry and Addiction Psychiatry.

<div align='center'>60</div>

Dr. Palumbo’s qualifications to serve as
our CMO is based on the decades and depth of experiences in the roles he has served in his medical profession and commercial experience
in the healthcare industry and biopharma industries.

Mr. Jim Lang, Chairman of the Board of
Directors since 2023 and has served as the Company’s director since 2016. He is currently CEO of EVERSANA, the leading commercialization
services company for the life sciences industry. In five years since he founded EVERSANA, it is now over $1B in revenue, with >7000
employees across 40 global locations. He formerly served as the CEO of Decision Resources Group (DRG), which he transformed into a leading
healthcare data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy Research Associates (IHS CERA), a recognized leader
in energy industry subscription information products, and formerly the President of Strategic Decisions Group (SDG), a leading global
strategy